LAUSR

1 Murrell DF, Amagai M, Barnadas M et al. Consensus statement on definitions of disease endpoints and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58:1043–6. 2 Murrell DF, Pe~ na S, Joly P et al. Diagnosis and management of pemphigus: recommendations by an International Panel of Experts. J Am Acad Dermatol 2018. https://doi.org/10.1016/j.jaad.2018.02.021 3 Hanna S, Kim M, Murrell DF. Validation studies of outcome measures in pemphigus. Int J Womens Dermatol 2016; 2:128–39. 4 Ormond M, McParland H, Donaldson ANA et al. An Oral Disease Severity Score validated for use in oral pemphigus vulgaris. Br J Dermatol 2018; 179:872–81. 5 Rosenbach M, Murrell DF, Bystryn J-C et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009; 109:2404–10. 6 Daniel BS, Hertl M, Werth VP et al. Severity score indexes for blistering diseases. Clin Dermatol 2012; 30:108–13. 7 Boulard C, Lehembre SD, Picard-Dahan C et al. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 2016; 175:142–9. 8 Murrell DF, Marinovic B, Caux F et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol 2015; 72:168–74.